KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Asset Writedowns and Impairment (2018 - 2019)

Historic Asset Writedowns and Impairment for Aquestive Therapeutics (AQST) over the last 2 years, with Q3 2019 value amounting to $6000.0.

  • Aquestive Therapeutics' Asset Writedowns and Impairment fell 8571.43% to $6000.0 in Q3 2019 from the same period last year, while for Sep 2019 it was $16000.0, marking a year-over-year change of. This contributed to the annual value of $53000.0 for FY2018, which is N/A changed from last year.
  • As of Q3 2019, Aquestive Therapeutics' Asset Writedowns and Impairment stood at $6000.0, which was down 8571.43% from $24000.0 recorded in Q2 2019.
  • Aquestive Therapeutics' 5-year Asset Writedowns and Impairment high stood at $42000.0 for Q3 2018, and its period low was -$20000.0 during Q4 2018.